Acceptability of levofloxacin dispersible and non-dispersible tablet formulations in children receiving TB preventive treatment
BACKGROUND: We evaluated the palatability and acceptability of a 100 mg dispersible and a non-dispersible 250 mg levofloxacin (LVX) tablet formulation in children. METHODS: Perform was a randomised, open-label, cross-over trial of the relative bioavailability of LVX dispersible vs. crushed non-dispe...
Saved in:
Main Authors: | D. T. Wademan, H. R. Draper, S. E. Purchase, M. Palmer, A. C. Hesseling, L. Van der Laan, A. J. Garcia-Prats |
---|---|
Format: | Article |
Language: | English |
Published: |
International Union Against Tuberculosis and Lung Disease (The Union)
2024-02-01
|
Series: | IJTLD Open |
Subjects: | |
Online Access: | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000002/art00003 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Children and providers’ perspectives on once-weekly rifapentine and isoniazid TB preventive therapy
by: A.J. Marthinus, et al.
Published: (2025-01-01) -
TB prevention activities in the WHO European Region
by: A. Matteelli, et al.
Published: (2024-08-01) -
Prevalence, incidence and determinants of QuantiFERONTM positivity in South African schoolchildren
by: J. Stewart, et al.
Published: (2024-05-01) -
3HP preventive treatment among children and adolescents with HIV and child household contacts of TB patients
by: A. Kinikar, et al.
Published: (2024-09-01) -
Burden and challenges in managing TB infection among people with occupational exposure to silica in India
by: B. Kalottee, et al.
Published: (2024-11-01)